ARUP Laboratories Joins Forces with CDC for Bird Flu Test Development
ARUP Laboratories has formed a crucial partnership with the CDC to develop tests for avian influenza A (H5N1), commonly known as bird flu. This collaboration positions ARUP alongside other renowned lab partners like Quest Diagnostics and Labcorp, ensuring swift responses to public health needs when they arise.
Dedication to Quality and Innovation
This partnership highlights the CDC's recognition of ARUP's impressive 40-year track record in the development of reliable diagnostic tests. Dr. Jonathan Genzen, ARUP's chief medical officer, shared his pride in ARUP’s commitment to public health and innovation, noting that being chosen as a partner emphasizes their dedication to developing high-quality tests.
New Approach to Public Health Strategy
This collaboration signifies a notable change in the CDC's strategy, which now allows commercial laboratories like ARUP to play a proactive role in the testing development process. This shift means tests for bird flu can be made available significantly faster in the event of a public health crisis, compared to previous situations.
According to Dr. Marc Couturier, head of clinical operations at ARUP, integral partnerships are vital in improving public health services. With this contract in place, ARUP is focused on ensuring its capacity to provide effective clinical laboratory testing solutions.
Recent Bird Flu Cases Raise Concern
Recent incidents underscore the urgency of this initiative. An individual has tested positive for an H5 virus without known exposure to poultry or birds, which raises alarms in public health. The CDC is continuing its investigation, and fast testing capabilities will be key in these cases. Since 2022, the CDC has reported 15 human cases of bird flu in the United States, with 14 of those occurring after April 2023.
Enhancing Testing Capabilities
This contract solidifies a significant relationship between ARUP and the CDC, creating numerous opportunities for collaboration in public health. Dr. Benjamin Bradley, medical director of the ARUP Institute for Research and Innovation, emphasized ARUP's ongoing commitment to enhancing its capabilities for rapidly responding to health crises as they come up.
ARUP's dedication to public health is reflected in its continuous investments in testing technologies for emerging infectious diseases. This initiative exemplifies ARUP's proactive stance towards public health and its capacity to scale testing operations as needed.
About ARUP Laboratories
Established in 1984, ARUP Laboratories is a nonprofit national reference laboratory associated with the University of Utah. Offering over 3,000 different tests, ARUP serves a wide range of clients, including leading university hospitals and governmental agencies. It has gained recognition for its innovative research and development in diagnostic services and holds accreditation under ISO standards.
ARUP remains committed to enhancing patient care and public health through its extensive testing initiatives, maintaining its position as a leader in the field.
Frequently Asked Questions
What is the purpose of the partnership between ARUP and the CDC?
The partnership focuses on swiftly developing testing solutions for avian influenza A (H5N1) to effectively meet public health needs.
How many labs are collaborating with the CDC alongside ARUP?
ARUP is one of five laboratory partners working with the CDC, which also includes Quest Diagnostics, Labcorp, Aegis Sciences, and Ginkgo Bioworks.
When was ARUP selected for this partnership?
The article doesn't specify a date, but it was mentioned during a media briefing that ARUP has been chosen to be part of this initiative.
What has changed in the CDC's approach toward lab partnerships?
The CDC is now enabling commercial labs to take a proactive role in developing testing solutions, rather than only responding during public health emergencies.
How many human bird flu cases have been reported in the U.S.?
According to the CDC, there have been a total of 15 human cases of bird flu reported in the United States since 2022.
